We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NortonLifeLock’s third-quarter fiscal 2021 non-GAAP earnings increased 52% from the year-ago quarter to 38 cents per share. Also, the bottom line beat the Zacks Consensus Estimate by 2.7%.
Revenues of $639 million also surpassed the consensus mark of $630 million and jumped 3% year over year. This outperformance was mainly driven by double-digit revenue growth by the company’s partner business. Strong demand, especially in Japan, for identity theft protection solutions such as dark web monitoring and ID advisor, was a positive.
NortonLifeLock Inc. Price, Consensus and EPS Surprise
Direct average revenue per user (ARPU) increased 1.2% year over year to $9.10 per month. Continued stabilization of direct customer count was a positive. The company’s direct customer count increased 900,000 year over year during the fiscal third quarter, bringing the total count to 21 million.
In the reported quarter, gross profit climbed 7.2% year over year to $552 million. Moreover, gross margin expanded 310 basis points (bps) to 86.4%.
Operating income on a non-GAAP basis jumped 45.5% year over year to $326 million. Operating margin was 51%, up significantly from 36.2%.
Balance Sheet
As of Jan 1, 2021, NortonLifeLock had $1.05 billion in cash and cash equivalents, flat sequentially. Long-term debt was $3.54 billion, down slightly from the $3.56 billion witnessed in the previous quarter.
The company used cash of $293 million for operational activities.
Guidance
For the fourth quarter of fiscal 2021, NortonLifeLock projects revenues between $655 million and $665 million.
Moreover, non-GAAP earnings from continuing operations are expected between 37 cents and 39 cents per share.
Outlook for the fourth quarter includes the partial impact of Avira acquisition.
Zacks Rank and Stocks to Consider
NortonLifeLock currently carries a Zacks Rank #3 (Hold).
The long-term earnings growth rate for Apple, Zoom Video Communications and Shopify is currently pegged at 11.5%, 25%, and 32.5%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
NortonLifeLock (NLOK) Q3 Earnings Beat Estimates, Rise Y/Y
NortonLifeLock’s third-quarter fiscal 2021 non-GAAP earnings increased 52% from the year-ago quarter to 38 cents per share. Also, the bottom line beat the Zacks Consensus Estimate by 2.7%.
Revenues of $639 million also surpassed the consensus mark of $630 million and jumped 3% year over year. This outperformance was mainly driven by double-digit revenue growth by the company’s partner business. Strong demand, especially in Japan, for identity theft protection solutions such as dark web monitoring and ID advisor, was a positive.
NortonLifeLock Inc. Price, Consensus and EPS Surprise
NortonLifeLock Inc. price-consensus-eps-surprise-chart | NortonLifeLock Inc. Quote
Quarter Details
Direct average revenue per user (ARPU) increased 1.2% year over year to $9.10 per month. Continued stabilization of direct customer count was a positive. The company’s direct customer count increased 900,000 year over year during the fiscal third quarter, bringing the total count to 21 million.
In the reported quarter, gross profit climbed 7.2% year over year to $552 million. Moreover, gross margin expanded 310 basis points (bps) to 86.4%.
Operating income on a non-GAAP basis jumped 45.5% year over year to $326 million. Operating margin was 51%, up significantly from 36.2%.
Balance Sheet
As of Jan 1, 2021, NortonLifeLock had $1.05 billion in cash and cash equivalents, flat sequentially. Long-term debt was $3.54 billion, down slightly from the $3.56 billion witnessed in the previous quarter.
The company used cash of $293 million for operational activities.
Guidance
For the fourth quarter of fiscal 2021, NortonLifeLock projects revenues between $655 million and $665 million.
Moreover, non-GAAP earnings from continuing operations are expected between 37 cents and 39 cents per share.
Outlook for the fourth quarter includes the partial impact of Avira acquisition.
Zacks Rank and Stocks to Consider
NortonLifeLock currently carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the broader technology sector include Apple Inc. (AAPL - Free Report) , Zoom Video Communications (ZM - Free Report) and Shopify (SHOP - Free Report) , all sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The long-term earnings growth rate for Apple, Zoom Video Communications and Shopify is currently pegged at 11.5%, 25%, and 32.5%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>